Abivax SA ADR (2X10)
XDUS 
Summary
2X10 Chart
People also search for
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Abivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with strong secondary endpoints and a favorable safety profile. A recent $920M capital raise funds operations into Q4 2029, enabling standalone commercialization and strengthening strategic positioning.
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.
Abivax SA ADR (2X10) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Abivax SA ADR ever had a stock split?
Abivax SA ADR Profile
| Biotechnology Industry | Healthcare Sector | Marc de Garidel CEO | XDUS Exchange | US00370M1036 ISIN |
| FR Country | 80 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ABIVAX Société Anonyme operates in the forefront of biotechnology with a focus on discovering and developing therapeutic solutions aimed at modulating the body's natural immune response. Founded in 2013 and with its headquarters in Paris, France, this clinical-stage company is dedicated to addressing chronic inflammatory diseases through innovative treatments. By leveraging the body's own regulatory mechanisms, ABIVAX aims to provide effective and potentially pioneering therapies for diseases that currently have limited treatment options.
Products and Services
- Obefazimod:
As the lead drug candidate of ABIVAX, obefazimod represents a significant advancement in the treatment of chronic inflammatory diseases. Currently, it is undergoing Phase 3 clinical trials for its efficacy against moderately to severely active ulcerative colitis in adults. This therapeutic approach underscores ABIVAX’s commitment to tackling unmet medical needs within the realm of inflammatory diseases through the utilization of the body's inherent mechanisms for restoring immune balance.
